Compare PTCT & MAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTCT | MAIN |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.8B |
| IPO Year | 2006 | 2014 |
| Metric | PTCT | MAIN |
|---|---|---|
| Price | $63.51 | $53.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 8 |
| Target Price | ★ $101.07 | $59.86 |
| AVG Volume (30 Days) | ★ 1.2M | 450.8K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 8.15% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | 0.90 | ★ 0.93 |
| Revenue | ★ $264,734,000.00 | N/A |
| Revenue This Year | N/A | $3.68 |
| Revenue Next Year | $9.26 | $6.91 |
| P/E Ratio | $71.38 | ★ $57.73 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $61.23 | $48.95 |
| 52 Week High | $90.87 | $65.23 |
| Indicator | PTCT | MAIN |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 36.28 |
| Support Level | $62.46 | $52.80 |
| Resistance Level | $72.86 | $57.95 |
| Average True Range (ATR) | 2.00 | 0.89 |
| MACD | 0.19 | -0.13 |
| Stochastic Oscillator | 38.57 | 10.76 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Main Street Capital Corp is a principal investment firm focused on providing customized long-term debt and equity capital solutions to lower middle market ("LMM") companies and debt capital to private ("Private Loan") companies owned by or in the process of being acquired by a private equity fund. The group invests principally in secured debt investments, equity investments, warrants, and other securities of LMM companies, typically based in the U.S. The company operates as a single segment with a principal investment objective to maximize total return by generating current income from debt investments and current income and capital appreciation from equity and equity-related investments.